Officially spun out of Ironwood Pharmaceuticals Inc., Cyclerion Therapeutics Inc. is recruiting new management experienced in both rare diseases and large indications, and gearing up for readouts from key programs in sickle cell disease, heart failure with preserved ejection fraction (HFpEF) and diabetic nephropathy.
Cambridge, Mass.-based Cyclerionofficially launched operations April 1 when its tax-exempt spinout from Ironwood – to develop a pipeline of soluble guanylate cyclase (sGC) stimulators – was finalized
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?